Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CCR2 | P41597 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9410053 | 1.00 | MAPT (0.36) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL30776774 | 0.95 | KDM4E (0.35) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL9766508 | 0.93 | MAPT (0.38) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL13158345 | 0.91 | L3MBTL1 (0.40) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL2303667 | 0.91 | MAPT (0.41) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL17138565 | 0.91 | L3MBTL1 (0.40) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL13158339 | 0.91 | CCR2 (0.41) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL12116735 | 0.89 | CCR2 (0.43) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL15958834 | 0.89 | CCR2 (0.43) | MAPTALDH1A1KDM4ECCR2L3MBTL1 | |
| SCHEMBL17138494 | 0.89 | CCR2 (0.40) | MAPTALDH1A1KDM4ECCR2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12246008-B2 | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME LLC (US) | 2025-03-11 | — | — | US | disclosed |
| CN-115023431-B | Triterpene compounds, pharmaceutical compositions thereof and use thereof in the treatment of diseases mediated by member 1 of the nuclear receptor subfamily 4 | 藤济(厦门)生物医药科技有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-116234546-A | GPX4 inhibitors, pharmaceutical compositions thereof and their use in the treatment of GPX4 mediated diseases | 嘉兴优博生物技术有限公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-3891157-A1 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | Merck Sharp & Dohme Corp. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020117626-A1 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2018134352-A1 | BICYCLIC AMINES AS NOVEL JAK KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-07-26 | — | — | WO | disclosed |
| EP-2493895-B1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | VECTURA LTD (GB) | 2017-04-26 | — | — | EP | disclosed |
| US-8946257-B2 | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | VECTURA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-20130289015-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | PALAU PHARMA, S.A. | 2013-10-31 | — | — | US | disclosed |
| US-8501735-B2 | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | PALAU PHARMA, S.A. (ES) | 2013-08-06 | — | — | US | disclosed |
| US-20060025349-A1 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-02 | — | — | US | disclosed |
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | CELLTECH R & D LIMITED (GB) | 2004-06-24 | — | — | US | disclosed |
| EP-1368366-A1 | NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES | Celltech R & D Limited (GB) | 2003-12-10 | — | — | EP | disclosed |
| US-20030105102-A1 | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting PARP activity | GUILFORD PHARMACEUTICALS INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002062816-A1 | NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES | CELLTECH R & D LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
| US-20020022636-A1 | OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY | GUILFORD PHARMACEUTICALS INC. | 2002-02-21 | — | — | US | disclosed |
| US-6235748-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2001-05-22 | — | — | US | disclosed |
| CN-1278797-A | Oxo-substituted compouns, process of making, and compositions and methods for inhibiting parp activity | GUILFORD PHARMACETICALS INC (US) | 2001-01-03 | — | — | CN | disclosed |
| EP-1009739-A2 | OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999011624-A1 | OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022636-A1 | OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY | PARP2, PARP1, PARP3 | MAPT 4366/4885ALDH1A1 1064/4885KDM4E 1776/4885 |
| US-20130289015-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | MAPT 4276/4885ALDH1A1 3830/4885KDM4E 2056/4885 |
| US-20030105102-A1 | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting PARP activity | PARP1, PARP3, PARP2 | MAPT 4077/4885ALDH1A1 870/4885KDM4E 1485/4885 |
| US-12246008-B2 | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels | TRPV1, SCN7A, SCN1A | MAPT 2601/4885ALDH1A1 892/4885KDM4E 1498/4885 |
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | P2RY1, P2RY11, P2RY13 | MAPT 4698/4885ALDH1A1 3697/4885KDM4E 4880/4885 |
| US-20060025349-A1 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | SLC5A1, SLC5A2, SLC2A1 | MAPT 2411/4885ALDH1A1 998/4885KDM4E 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.